4-Methylmorpholine → HCID 57959382, compound
Reaction equation
[NH2:1][CH2:2][C:3]1[CH:4]=[C:5]([S:9]([NH:12][CH2:13][CH2:14][NH:15][C:16](=[O:22])[O:17][C:18]([CH3:21])([CH3:20])[CH3:19])(=[O:11])=[O:10])[CH:6]=[CH:7][CH:8]=1.[C:23]1([C:29]2[N:34]=[CH:33][C:32]([C:35](O)=[O:36])=[CH:31][N:30]=2)[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1.C1C=CC2N(O)N=NC=2C=1.CN1CCOCC1.Cl.CN(CCCN=C=NCC)C>CN(C)C=O.C(OCC)(=O)C>[C:23]1([C:29]2[N:34]=[CH:33][C:32]([C:35]([NH:1][CH2:2][C:3]3[CH:4]=[C:5]([S:9]([NH:12][CH2:13][CH2:14][NH:15][C:16](=[O:22])[O:17][C:18]([CH3:19])([CH3:21])[CH3:20])(=[O:10])=[O:11])[CH:6]=[CH:7][CH:8]=3)=[O:36])=[CH:31][N:30]=2)[CH:24]=[CH:25][CH:26]=[CH:27][CH:28]=1Participants
Reactant 5
Product 1
Reagents, catalysts & solvents 2
Procedure
To a mixture consisting of tert-butyl 2-(3-(aminomethyl)phenylsulfonamido)ethylcarbamate (Compound 16, 278 mg), 2-phenylpyrimidine-5-carboxylic acid (Compound 17; synthesis described in Example 1, Steps 1-3 of WO 2007/041634 to Aldous et al., entitled “Pyrimidine Amide Compounds as PGDS Inhibitors”; 182 mg), HOBt (123 mg), and N-methyl-morpholine (0.11 mL) in N,N-dimethylformamide (11 mL) was added 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (287 mg) and the mixture was stirred for 2.5 hours. The crude reaction mixture was diluted with ethyl acetate and washed with brine. The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The residue was purified by silica chromatography (5:95 methanol-dichloromethane) to afford the title intermediate (363 mg, 87%); MS (ESI−) m/z 510 (M−1).
Workup
- customThe crude reaction mixture
- washwashed with brine
- dry with materialThe organic phase was dried (MgSO4)
- filtrationfiltered
- concentrationconcentrated under reduced pressure
- customThe residue was purified by silica chromatography (5:95 methanol-dichloromethane)
Sources & evidence
- ORD record
- ord-a4c495fe319943ffbba49c425690a7b5
- Source dataset
- uspto-grants-2013_05
- Patent number
- US08440417B2
Reaction notes
Loading…